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Abstract
Golestan Province in northern Iran is an area with a high incidence of esophageal squamous cell carcinoma (ESCC). We
aimed to investigate prognostic factors for ESCC and survival of cases in Golestan, on which little data were available. We
followed-up 426 ESCC cases participating in a population-based case-control study. Data were analyzed using the Kaplan–
Meier method and the Cox proportional hazard models. Median survival was 7 months. Age at diagnosis was inversely
associated with survival, but the association was disappeared with adjustment for treatment. Residing in urban areas
(hazard ratio, HR= 0.70; 95% CI 0.54–0.90) and being of non-Turkmen ethnic groups (HR= 0.76; 95% CI 0.61–0.96) were
associated with better prognosis. In contrast to other types of tobacco use, nass (a smokeless tobacco product) chewing
was associated with a slightly poorer prognosis even in models adjusted for other factors including stage of disease and
treatment (HR= 1.38; 95% CI 0.99–1.92). Opium use was associated with poorer prognosis in crude analyses but not in
adjusted models. Almost all of potentially curative treatments were associated with longer survival. Prognosis of ESCC in
Golestan is very poor. Easier access to treatment facilities may improve the prognosis of ESCC in Golestan. The observed
association between nass chewing and poorer prognosis needs further investigations; this association may suggest a
possible role for ingestion of nass constituents in prognosis of ESCC.
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Introduction
Esophageal cancer is the 6th cause of cancer death worldwide
[1,2]. The incidence of esophageal cancer has high geographical
variation, ranging from 3 per 100,000 person-years in low
incidence areas to over 100 per 100,000 in high incidence regions
of China and in Golestan Province in northern Iran [3]. Although
during the past few decades the number of esophageal
adenocarcinoma cases has been increasing in several Western
countries [4,5], ESCC is still the most common histological
subtype of esophageal cancer worldwide, particularly in high
incidence areas. For example, approximately 90% of all
esophageal cancers in Golestan Province are ESCC [6].
Overall, ESCC has a poor prognosis [2,7]. The outcome of
ESCC is mainly determined by age, the stage of cancer at
presentation, and type of treatment [8]. Long term survival is
mainly reported in a fairly small proportion of cases whose disease
is limited to mucosa or submucosa of the oesophagus and who
receive appropriate treatment [9,10]. Several other prognostic
factors for ESCC, e.g. sex, race and socioeconomic status [11,12],
have been reported but the results are not as consistent as for the
above factors. A few studies have suggested that the prognosis may
be influenced by etiologic factors of ESCC, e.g. tobacco use
[13,14,15]; however, the evidence is limited.
Although ESCC is the most common cancer in Golestan [16],
no population-based data from the region are available on
prognosis and survival of this cancer . In order to address this
issue, we followed up the ESCC cases who had participated in
Golestan Case-Control Study, a recent population-based study on
upper gastrointestinal cancers in Golestan. We investigated the
relation of survival in ESCC cases with several suggested
prognostic factors in the literature and risk factors for ESCC in
Golestan, including opium and tobacco use [17,18].
Materials and Methods
Details of the original case-control study are available elsewhere
[6,18]. Briefly, physicians in the study field were asked to refer all
patients suspected of having upper gastrointestinal tract cancer to
Atrak Clinic, the only specialized clinic for upper gastrointestinal
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cancers in Eastern Golestan, where all the patients underwent
oesophago-gastro-duodenal videoendoscopy. The process of
identifying cases was not based on a screening program; the
individuals underwent usual diagnostic procedures. Biopsy speci-
mens were collected using a standard protocol and examined by
experienced pathologists. All individuals who diagnosed with
ESCC from 2002 to 2007 and agreed to participate were recruited
in the current study. Other eligibility criteria were being at least 18
years of age, residing in the study area at the time of registration,
and having no history of any other cancer. Results of the Golestan
Cancer Registry show that approximately 70% of all incident cases
in the study area were referred to Atrak Clinic during the period of
study (unpublished results). For almost all cases, ESCC was
diagnosed for the first time. Participants were interviewed by
trained interviewers who collected detailed information on
demographic and lifestyle characteristics, including tobacco,
opium and alcohol use, using a structured questionnaire. Data
on common tobacco products in the region were collected
separately: i.e. cigarette, hookah (water pipe), and nass (a chewing
tobacco product which is a mixture of tobacco, lime, and ash). The
questionnaire for tobacco and opium use had been validated
against urine cotinine, codeine, and morphine level [19]. Location
of tumors within the oesophagus was determined by experienced
gastroenterologists using data collected during the first endoscopy
at Atrak Clinic.
Every three month an experienced nurse contacted the study
participants by telephone and asked about their general condition,
ability to swallow, and treatment process. In case of death,
information on the exact date of death, place of death (hospital
versus home), and the reason for death was collected from close
relatives of cases. When any telephone number was not available
or phone contacts were unsuccessful, a team consisted of a
physician and a nurse visited cases or their family at home to
collect the above information. The patients were followed from the
date of diagnosis until death or the end of the study (June 2008)
whichever occurred first.
We attempted to collect reports of laboratory tests, imaging
procedures, surgical operative notes, and surgical pathology
reports for any participant who underwent those procedures
[20]. The planned staging procedure was as following: chest X-ray
and abdominal sonography followed by thoracic and abdominal
computed tomography (CT) scan (spiral high speed). When all of
the above examinations did not show any evidence of metastasis,
the cases were referred to Digestive Disease Research Center
(DDRC) of Tehran University of Medical Sciences in Tehran for
endoscopic ultrasonography of esophageal tumor, which was free
of charge. PET-CT scan was not available for staging in the study
area or at DDRC during the study period. CT scan was not also
available by 2004 in Eastern Golestan. All participants, including
those who refused the above staging process, were finally referred
to treatment centers. However, a substantial number of cases
refused further workup for staging or treatment outside the study
field. We could collect completed information on staging for only
28.6% of participants. Staging was done using the American Joint
Committee on Cancer’s staging system [21]. In the first step,
staging was done clinically using history of dysphagia and other
major symptoms and routine laboratory analyses, such as liver
function tests, plus (1) abdominal sonography and chest x-ray and/
or (2) spiral CT scan of thorax and abdomen [20]. When such
information was not available, the tumor stage was classified as
‘unknown’. Otherwise, tumors were staged as following. ESCC
was categorized as stage IV when there was evidence of distant
metastasis. In other cases, the final staging was dependent on
information regarding local progression of tumor, such as data
from endoscopic ultrasonography and/or surgery. When such
information was not available, tumors were included among those
with ‘unknown’ staging. Stage I was assigned when tumor invaded
lamina propria or submocusa only. Tumors were classified as stage
II when tumor invaded muscularis propria or adventitia without
any involvement of lymph node or when the extension of tumor
was similar to that of stage I but with involvement of regional
lymph nodes. Stage III was assigned when tumor invaded
adventitia with involvement of regional lymph nodes or when
tumor invaded adjacent structures; many of the latter cases were
staged in the first step using information from CT scans.
Cigarette, hookah, nass, and opium users were defined as
individuals who had ever used the respective substances at least
once per week for a minimum duration of 6 months. Those who
had started using any tobacco product or opium within one year
before diagnosis of their disease were considered as non-users. We
did not include alcohol drinking in our analyses, as few
participants were alcohol drinker [18]. Demographic and lifestyle
characteristics were based on the information that was recorded at
diagnosis.
We categorize the treatments that participants received as: (1)
no surgery, chemotherapy, or radiotherapy; (2) only surgery; (3)
surgery plus chemotherapy; (4) surgery plus radiotherapy; (5)
surgery plus chemoradiotherapy; (6) only chemotherapy; (7) only
radiotherapy; and (8) only chemoradiotherapy. As detailed
information was not available on the chemotherapy and radio-
therapy regimens that were used, individuals who received any
regimen (even uncompleted) were categorized as recipient of the
respective treatment.
Written informed consent was obtained from all participants.
The study was reviewed and approved by the Institutional Review
Board of DDRC at Tehran University of Medical Sciences.
Statistical analysis
Survival probability for all participants combined and by
treatment was calculated using the Kaplan-Meier method. Hazard
ratios (HR) and corresponding 95% confidence intervals (CI) for
the influence of several variables of interest on survival were
estimated using the Cox proportional hazards regression models.
Results for univariate and two multivariate models are presented.
The first multivariate model was adjusted for age (categorical), sex,
place of residence, ethnicity, nass chewing, and stage of the
disease. The second model was further adjusted for the type of
treatment received. As an attempt to identify indicators of
receiving potentially curative treatment, which showed a strong
association with survival, we examined correlation of several
demographic factor and nass chewing with receiving surgery and
any curative treatment for ESCC. Correlation coefficients and p-
values were derived from multivariate logistic models in which
treatments were dependent variables and place of residence,
ethnicity, age, sex, nass chewing and stage of ESCC (I/II, III, IV,
unknown) were included as independent variables. As place of
residence was correlated with ethnicity, we examined interaction
between these two variables with regard to receiving treatments
using similar logistic models. All statistical analyses were
performed using Stata (StataCorp LP, TX, USA; version 11)
statistical software. All statistical tests were two-sided.
Results
A total of 449 cases of ESCC were eligible for this study. Follow
up data were not completed for 23 cases (5.1%) due to change in
their living address, so they were excluded from this study and data
from 426 individuals were used for current analysis. The overall
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survival estimation curve is presented in Figure 1. The median
survival was 7 months. Five-year survival rate was 3.3%. ESCC
cases who received any potentially curative treatment and surgery
had longer survival (Figure 2; p-values,0.0001).
The HRs and 95% CIs for patient and tumor characteristics are
shown in Table 1. While in the Adjusted Model 1 older age was
associated with poorer prognosis, the association was disappeared
after further adjustment for treatment. The HR (95% CI) was 1.22
(0.90–1.66) for age 66–75 years and 1.23 (0.85–1.77) for age $76
years in the Adjusted Model 2. Men did not have poorer prognosis
than women (HR=1.10; 95% CI 0.87–1.38). Both residing in
urban areas (HR=0.70; 95% CI 0.54–0.90) and being of non-
Turkmen ethnic groups (HR=0.76; 95% CI 0.61–0.96) were
associated with better prognosis. With regard to the use of tobacco
products and opium, only nass chewing showed significant
association with poorer prognosis (HR=1.57; 95% CI 1.13–
2.18). With further adjustment for treatment, the association was
still borderline significant (HR=1.38; 95% CI 0.99–1.92).
Location of tumor was not significantly associated with
survival. Only one participant had stage I of the disease, so we
combined stages I and II for further analyses. More-advanced
stages of ESCC were associated with poorer prognosis in
Adjusted Model 1: the HR (95% CI) was 1.48 (0.93–2.34) for
stage III, 1.93 (1.05–3.56) for stage IV, and 1.83 (1.24–2.70) for
unknown stage compared to stages I and II combined. Except for
chemotherapy alone, other therapies were associated with longer
survival in the multivariate model (Table 1). The best result was
observed with surgery plus chemoradiotherapy (HR=0.18; 95%
CI 0.10–0.31).
Distribution of individuals who received potentially curative
treatments was highly varied among categories of place of
residence and ethnicity (Table S1). Table 2 shows correlation
coefficients (95% CIs) and p-values for several factors and
receiving surgery or any curative treatment for ESCC. Place of
residence did not show significant correlation with receiving
treatment. Being of non-Turkmen ethnic group was correlated
with receiving surgery (P=0.006) and any curative treatment
(P=0.01). There was no interaction between place of residence
and ethnicity with regard to surgery (P=0.92), but the interaction
was borderline significant for any curative treatment (P=0.06).
Age was strongly correlated with lower rates of receiving
treatments. Nass chewer received less curative treatment than
non-chewers (P=0.003), but the difference with regard to surgery
was not significant.
Discussion
Our study showed very poor prognosis of ESCC in Golestan.
We found worse prognosis of ESCC with higher age, residing in
rural areas, being of Turkmen ethnic group, history of nass
chewing, having more advanced disease, and not receiving
potentially curative treatments. Turkmens, older patients and nass
chewers were less likely to receive curative treatments.
Five-year survival rates of ESCC cases are usually less than 20%
[22]. The majority of reports on survival among ESCC cases come
from hospital-based studies that investigated treatment modalities
and relevant prognostic factors in relation to survival of selected
patients undergoing those treatments, such as surgery. There are
also several studies that reported survival rates for ESCC cases in the
general population [7,11,12,13,23,24,25,26,27,28]. In the majority
of these studies, five-year survival rates were reported as
approximately 10% [11,12,13,24,27,28]. Survival rates in our study
were consistent with those from a recent study in northwest of Iran,
in which overall survival was reported as 40.5% for one year, 6.5%
for three years, and 0.8% for five years [23]. The survival rates in
both above studies in Northern Iran and in some other low- to
moderate-income countries [29,30] are generally lower than the
rates reported in studies from high-income countries (see above).
Figure 1. Survival of participants with esophageal squamous
cell carcinoma in Golestan Province, Iran.
doi:10.1371/journal.pone.0022152.g001
Figure 2. Survival of participants with esophageal squamous
cell carcinoma by treatment (p-values come from log-rank
tests for equality of survivor functions).
doi:10.1371/journal.pone.0022152.g002
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Consistent with the literature [27,8,25], survival was inversely
associated with age in our study. This association remained
significant even after adjustment for stage of disease and
demographic and lifestyle characteristics. However, this associa-
tion was strongly attenuated with adjustment for treatment,
suggesting that survival among older and younger ESCC cases
may not be much different if the same treatment can be
administered. Our study showed an inverse correlation between
age and receiving surgery or any curative treatment for ESCC.
Older patients may be more likely to be considered as not eligible
Table 1. Hazard ratios and 95% confidence intervals for death by patient and tumor characteristics.
HR (95% CI)
Characteristics Number (%) Non-adjusted Model Adjusted Model 1a Adjusted Model 2a
Age group (years)
,56 90 (21.1) Reference Reference Reference
56–65 116 (27.2) 0.82 (0.60–1.13) 0.86 (0.63–1.19) 0.70 (0.50–0.98)
66–75 144 (33.8) 1.48 (1.11–1.99) 1.65 (1.23–2.22) 1.22 (0.90–1.66)
$76 76 (17.8) 2.11 (1.52–2.94) 2.05 (1.45–2.89) 1.23 (0.85–1.77)
P for trend ,0.001 ,0.001 0.01
Sex
Women 215 (50.5) Reference Reference Reference
Men 211 (49.5) 1.17 (0.95–1.44) 1.04 (0.83–1.30) 1.10 (0.87–1.38)
Place of residence
Rural 304 (71.4) Reference Reference Reference
Urban 122 (28.6) 0.78 (0.62–0.99) 0.75 (0.58–0.95) 0.70 (0.54–0.90)
Ethnicity
Turkmen 228 (53.5) Reference Reference Reference
Non-Turkmen 198 (46.5) 0.73 (0.59–0.90) 0.76 (0.61–0.95) 0.76 (0.61–0.96)
Tobacco and opium useb
Cigarette 73 (17.3) 1.05 (0.79–1.38) 0.85 (0.62–1.15) 0.85 (0.62–1.18)
Hookah (water pipe) 33 (7.8) 1.22 (0.84–1.78) 1.32 (0.88–1.98) 1.22 (0.81–1.83)
Nass chewing 50 (11.8) 1.85 (1.36–2.51) 1.57 (1.13–2.18) 1.38 (0.99–1.92)
Opium use 131 (31.0) 1.23 (0.98–1.54) 1.09 (0.86–1.39) 1.06 (0.83–1.35)
Tumor location
Upper One third 38 (8.9) Reference Reference Reference
Middle one third 220 (51.6) 0.83 (0.58–1.21) 0.89 (0.61–1.30) 0.92 (0.63–1.36)
Lower one third 127 (29.8) 0.88 (0.60–1.30) 0.96 (0.65–1.43) 0.94 (0.63–1.40)
Unknown 41 (9.6) 0.62 (0.37–1.04) 0.65 (0.38–1.11) 0.80 (0.47–1.37)
Staging
I/II 43 (10.1) Reference Reference Reference
III 61 (14.3) 1.48 (0.94–2.33) 1.48 (0.93–2.34) 1.09 (0.67–1.76)
IV 18 (4.2) 1.59 (0.87–2.92) 1.93 (1.05–3.56) 1.47 (0.78–2.76)
P for trend ,0.001 0.002 0.27
Unknown 304 (71.4) 1.98 (1.36–2.90) 1.83 (1.24–2.70) 1.25 (0.83–1.89)
Treatment
Nonec 208 (48.8) Reference Reference -
Only surgery 43 (10.1) 0.30 (0.21–0.45) 0.32 (0.21–0.49) -
Surgery+chemotherapy 24 (5.6) 0.19 (0.11–0.33) 0.26 (0.14–0.48) -
Surgery+radiotherapy 6 (1.4) 0.31 (0.11–0.85) 0.52 (0.19–1.46) -
Surgery+chemoradiotherapy 29 (6.8) 0.18 (0.10–0.30) 0.18 (0.10–0.31) -
Only chemotherapy 26 (6.1) 0.79 (0.51–1.22) 1.02 (0.65–1.62) -
Only radiotherapy 34 (8.0) 0.63 (0.43–0.92) 0.67 (0.46–0.99) -
Only chemoradiotherapy 56 (13.2) 0.29 (0.20–0.41) 0.30 (0.21–0.44) -
aAdjusted 1 model included other variables in the list excluding tumor location and treatment. Adjusted model 2 was further adjusted for treatment.
bThe reference group was the participants who did not use the respective substance.
cNo surgery, chemotherapy or radiotherapy.
doi:10.1371/journal.pone.0022152.t001
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for or refuse more aggressive treatments, particularly surgery.
Therefore, they may not receive the treatments that are usually
administered to younger patients with a similar stage of disease.
The association of ethnicity/race [31,25,32] and place of
residence [31] with survival of esophageal cancer cases have been
reported in several studies mainly from United States. These
associations are not totally explainable by difference in stage at
diagnosis. The disparity has been attributed to several factors,
including lower socioeconomic status, a later stage at presentation,
a higher rate of comorbidities, more difficult access to medical
centers, and a lower rate of surgical resection in certain
populations. Both place of residence and ethnicity were significant
prognostic factors in current study, and ethnicity showed a strong
correlation with receiving potentially curative treatments for
ESCC, with a potential effect modification from place of residence
(but not with regard to surgery). Iran has nationwide health
insurance coverage for the inpatient services that are provided in
public hospitals. Health insurance for outpatient services is
provided to some degree for rural dwellers; for other individuals,
it depends on the coverage provided by workplaces for non-short
term employees and their family members. On the other hand,
although esophagectomy is done in the study area (Eastern
Golestan), the hospital volume for providing the surgery and its
intensive post-operation care can be limited. Furthermore, no
medical canter in Eastern Golestan provides all potentially
curative treatments, i.e. surgery, chemotherapy, and radiotherapy,
together. Therefore, ESCC patients have to travel to other cities to
receive combination therapies. More patients from urban than
rural areas may afford frequent travelling, and consequently they
may more easily consent to more appropriate and receive more
complete treatments, which may take longer durations particularly
with radiotherapy and chemotherapy. However, we did not have
data on initially proposed treatments by doctors and on
completeness of treatment. Potential cultural differences between
Turkmens and non-Turkmens in seeking for and/or giving
consent to more aggressive treatments, including esophagectomy,
may also play a role.
A few studies have reported an association between tobacco
smoking and poor prognosis in esophageal cancer [13,14,15].
However, such an association was not reported from Northwest of
Iran [23]. We found no association between cigarette smoking and
survival, but nass chewing was associated with poorer prognosis in
our study. Although tobacco chewing has been linked to
development of ESCC [33,34], little information is available on
the association between this habit and prognosis of ESCC. We can
only speculate on the reasons for this association. Other smoking-
related disorders may contribute to earlier death of ESCC cases.
In this case, it should also be true for many other cancer types.
Tobacco may have a direct effect on tumor progression or may
increase mortality from complications of treatment modalities, but
we did not observe a similar association with cigarette smoking.
Other components of nass may also have adverse influences. On
the other hand, nass chewing is much more common in rural areas
of Golestan, particularly among Turkmen males [35]. Another
explanation could be that nass chewing may be a proxy for
another poor prognosis factor that is associated with residing in
rural areas and being of Turkmen ethnic group. Further studies
are required to investigate whether or not the association between
nass and survival in ESCC cases is casual. The use of opium as a
traditional treatment for pain, diarrhea, and insomnia in Golestan
is fairly common [35]. Although opioids may promote angiogen-
esis and proliferation of tumor cells in vitro and in vivo [36,37], we
did not find a significant association between opium use and
survival of ESCC cases. This is similar to results of a study in
Northwest of Iran, which had a small number of opium users
though [23].
Similar to the previous literature, more advanced disease was
associated with poorer prognosis. On the other hand, patients with
advanced cancer at the time of diagnosis may die earlier than
those with less-advanced disease due to lead time bias. In our study
no screening was planned; patients were referred to Atrak Clinic
for clinical diagnosis of ESCC, and in the majority of cases ESCC
was diagnosed for the first time. We did not have reliable
information regarding the starting time of symptoms to take into
account lead time bias in our models. However, because dysphagia
as the chief complain of patients happens quiet late in the process
of disease and ESCC is a rapidly-progressing cancer, we believe
that there was no large variation in the time between the start of
symptoms and visiting the clinic, and consequently, major lead
time bias was unlikely.
Surgical resection is the gold standard for management of
patients with resectable ESCC [13,38]. However, fewer than half
Table 2. Coefficients for correlation of demographic characteristics and nass chewing with receiving surgery or any curative
treatment.
Surgery Any curative treatment
b (95% CI) P b (95% CI) P
Urban dwellers 0.40 (20.15–0.96) 0.16 0.31 (20.17–0.79) 0.21
Non-Turkmens 0.72 (0.21–1.23) 0.006 0.56 (0.13–1.00) 0.01
Interaction of place of residence and
ethnicity
0.06 (21.08–1.20) 0.92 0.94 (20.04–1.93) 0.06
Age (years)
56–65 20.83 (21.45–20.21) 0.009 20.29 (20.90–0.31) 0.34
66–75 21.33 (21.96–20.70) ,0.001 20.81 (21.39–20.23) 0.006
$76 23.44 (24.94–21.94) ,0.001 21.76 (22.48–21.04) ,0.001
Men 0.43 (20.08–0.93) 0.10 0.36 (20.08–0.79) 0.11
Nass chewers 20.72 (21.68–0.24) 0.14 21.07 (21.78–20.36) 0.003
Correlation coefficients and p-values come from multivariate logistic models in which all other variables listed in the table (excluding the interaction) and stage of ESCC
(I/II, III, IV, unknown) were included. Reference categories were rural dwellers, Turkmens, age ,56 years, women and those who never chewed nass.
doi:10.1371/journal.pone.0022152.t002
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of newly diagnosed cases have totally resectable cancer [39]. The
proportion of esophageal cancer cases who present with advanced
disease may be higher in some populations, particularly in low/
middle income countries [29,24]. Other therapeutic modalities are
usually used when surgical resection is not feasible or not
consented. However, combination of chemotherapy and/or
radiotherapy with surgery may be associated with more favourable
prognosis than surgery alone [38,40]. In our study, potentially
curative treatment was also strongly associated with a more
favourable prognosis. An earlier study in Northern Iran reported
survival rates among ESCC patients treated with radiotherapy.
The rates were 42% for one-year, 11% for three-year, and 8% for
five-year survival [41]. Another study reported a much higher five-
year survival rate (42%) for the ESCC cases who received
combination therapy [42]. However, approximately 45% of cases
in that study had stage I or II of the disease. Results of our study
did not come from a randomized trial, so they should not be
considered as a guideline for treatment of ESCC in the region.
Nevertheless, they indicate the importance of availability of
relevant facilities and encouraging ESCC cases to undergo
potentially curative treatments when indicated.
An association between sex and survival in multivariate models
has been reported, with women having longer survival
[11,39,43,44]. However, several other studies did not show such
a difference [23,24,41,25] or reported different patterns according
to treatment modalities [12]. In our study, men and women had
little difference in terms of survival.
The main strengths of the current study include the population-
based design with a large number of incident cases and high
success rate of follow up (completeness of follow up= 94.9%). As
one of major limitations of our study, staging data were not
available for many participants. We considered the participants
with unknown staging as a separate group; the overall prognosis of
which was in between of stages III and IV, suggesting that the
majority of those participants had stages III or IV. Most of the
available staging data in our study were mainly based on the
imaging procedures, such as CT scan, that may have limited
sensitivity in assessing lymph nodes and identifying metastasis and
can lead to misclassification [45,46]. However, because the
majority of cases presented with advanced disease, in many cases
imaging procedures were sufficient to detect local or distant
extension of tumor. For the above reasons, we do not expect
considerable distortion of other associations in the adjusted models
by current staging data. Data on socioeconomic status indicators,
including education level, was only available for less than half of
participants. The other participants had been enrolled in the pilot
phase of the Golestan Case-Control Study, in which data on
personal education level were not collected. When we considered
socioeconomic status for the subgroup for which such information
was available, study power was not enough to derive reliable
conclusions. Therefore, we were not able to investigate socio-
economic indicators in relation to survival. We did not have data
on access of the study participants to treatment and cancer care
facilities, as well as on patients’ compliance to different treatment
modalities. This limits our conclusion on relation of demographic
variables to survival.
In summery, prognosis of ESCC in Golestan is very poor. We
found several factors that were associated with survival of ESCC
cases, among which were stage of disease and history of receiving
potentially curative treatments. Easier access to treatment facilities
may improve the prognosis of ESCC in Golestan. We observed an
association between nass chewing and poorer prognosis, whereas
tobacco smoking was not associated with prognosis of ESCC. This
association may suggest a possible role for ingestion of tobacco
and/or other nass constituents in prognosis of ESCC. As survival
of ESCC patients is still poor worldwide, it is also essential to
identify and reduce the exposure to preventable risk factors of
ESCC.
Supporting Information
Table S1 Age, stage of ESCC, and treatment distributions by
place of residence and ethnicity.
(DOC)
Acknowledgments
We would like to thank the Iranian Social Security Organization for their
strong local support. We thank Ms. Halimeh Eskandarnejhad, Ms. Golnaz
Gharnas, and Ms. Maral Eskandarnejhad for conducting telephone
interviews.
Author Contributions
Conceived and designed the experiments: KA H-AM DN FI R. Shakeri
RM. Performed the experiments: KA DN FI B-AA M-RG ER EK SM
YM RR. Analyzed the data: DN FI. Contributed reagents/materials/
analysis tools: SM R. Sotoudehmanesh SS RM. Wrote the paper: KA H-
AM DN FI RM. Read and commented on the manuscript and approved
the final version: KA H-AM DN FI R. Shakeri MS B-AA M-RG ER EK
SM YM RR SM R. Sotoudehmanesh SS RM.
References
1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to reduce
cancer disparities in different geographic regions of the world. J Clin Oncol 24:
2137–2150.
2. Jemal A, Center MM, Desantis C, Ward EM (2010) Global patterns of cancer
incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:
1893–1907.
3. Blot WJ, McLaughlin JK, Fraumeni JF (2006) Esophageal Cancer. In:
Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. New
York: Oxford University Press. pp 697–706.
4. Trivers KF, Sabatino SA, Stewart SL (2008) Trends in esophageal cancer
incidence by histology, United States, 1998–2003. Int J Cancer 123: 1422–1428.
5. Steevens J, Botterweck AA, Dirx MJ, van den Brandt PA, Schouten LJ (2010)
Trends in incidence of oesophageal and stomach cancer subtypes in Europe.
Eur J Gastroenterol Hepatol 22: 669–678.
6. Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, et al. (2004)
Epidemiologic features of upper gastrointestinal tract cancers in Northeastern
Iran. Br J Cancer 90: 1402–1406.
7. Klint A, Engholm G, Storm HH, Tryggvadottir L, Gislum M, et al. (2010)
Trends in survival of patients diagnosed with cancer of the digestive organs in
the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 49:
578–607.
8. Wang LS, Chow KC, Chi KH, Liu CC, Li WY, et al. (1999) Prognosis of
esophageal squamous cell carcinoma: analysis of clinicopathological and
biological factors. Am J Gastroenterol 94: 1933–1940.
9. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, et al. (2008)
Predicting systemic disease in patients with esophageal cancer after esopha-
gectomy: a multinational study on the significance of the number of involved
lymph nodes. Ann Surg 248: 979–985.
10. Lin CS, Chang SC, Wei YH, Chou TY, Wu YC, et al. (2009) Prognostic
variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 87:
1056–1065.
11. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, et al. (2005)
Demographic and lifestyle predictors of survival in patients with esophageal or
gastric cancers. Clin Gastroenterol Hepatol 3: 225–230.
12. Steyerberg EW, Neville B, Weeks JC, Earle CC (2007) Referral patterns,
treatment choices, and outcomes in locoregional esophageal cancer: a
population-based analysis of elderly patients. J Clin Oncol 25: 2389–2396.
13. Sundelof M, Lagergren J, Ye W (2008) Patient demographics and lifestyle factors
influencing long-term survival of oesophageal cancer and gastric cardia cancer in
a nationwide study in Sweden. Eur J Cancer 44: 1566–1571.
14. Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, et al. (2009) p53
Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer
prognosis. Clin Cancer Res 15: 3103–3109.
Prognosis of OSCC in Golestan, Iran
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22152
15. Shitara K, Matsuo K, Hatooka S, Ura T, Takahari D, et al. (2010) Heavy
smoking history interacts with chemoradiotherapy for esophageal cancer
prognosis: a retrospective study. Cancer Sci 101: 1001–1006.
16. Semnani S, Sadjadi A, Fahimi S, Nouraie M, Naeimi M, et al. (2006) Declining
incidence of esophageal cancer in the Turkmen Plain, eastern part of the Caspian
Littoral of Iran: a retrospective cancer surveillance. Cancer Detect Prev 30: 14–19.
17. Cook-Mozaffari PJ, Azordegan F, Day NE, Ressicaud A, Sabai C, et al. (1979)
Oesophageal cancer studies in the Caspian Littoral of Iran: results of a case-
control study. Br J Cancer 39: 293–309.
18. Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, et al.
(2008) Opium, tobacco, and alcohol use in relation to oesophageal squamous cell
carcinoma in a high-risk area of Iran. Br J Cancer 98: 1857–1863.
19. Abnet CC, Saadatian-Elahi M, Pourshams A, Boffetta P, Feizzadeh A, et al.
(2004) Reliability and validity of opiate use self-report in a population at high risk
for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev 13:
1068–1070.
20. Thompson WM, Halvorsen RA, Foster WL, Jr., Williford ME, Postlethwait RW,
et al. (1983) Computed tomography for staging esophageal and gastroesophageal
cancer: reevaluation. AJR Am J Roentgenol 141: 951–958.
21. American Joint Committee on Cancer (2002) AJCC Cancer Staging Manual.
New York: Springer-Verlag.
22. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin
60: 277–300.
23. Samadi F, Babaei M, Yazdanbod A, Fallah M, Nouraie M, et al. (2007) Survival
rate of gastric and esophageal cancers in Ardabil province, North-West of Iran.
Arch Iran Med 10: 32–37.
24. Yeole BB, Kumar AV (2004) Population-based survival from cancers having a
poor prognosis in Mumbai (Bombay), India. Asian Pac J Cancer Prev 5:
175–182.
25. Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, et al. (2008) Racial
disparities in esophageal cancer treatment and outcomes. Ann Surg Oncol 15:
881–888.
26. Stockeld D, Backman L, Fagerberg J, Granstrom L (2007) Esophageal cancer in
Stockholm county 1978–1995. Acta Oncol 46: 1075–1084.
27. Faivre J, Forman D, Esteve J, Gatta G (1998) Survival of patients with
oesophageal and gastric cancers in Europe. Eur J Cancer 34: 2167–2175.
28. Baastrup R, Sorensen M, Hansen J, Hansen RD, Wurtzen H, et al. (2008) Social
inequality and incidence of and survival from cancers of the oesophagus,
stomach and pancreas in a population-based study in Denmark, 1994–2003.
Eur J Cancer 44: 1962–1977.
29. Alidina A, Gaffar A, Hussain F, Islam M, Vaziri I, et al. (2004) Survival data and
prognostic factors seen in Pakistani patients with esophageal cancer. Ann Oncol
15: 118–122.
30. Abdullah M, Karim AA, Goh KL (2010) Late presentation of esophageal cancer:
observations in a multiracial South-East Asian population. J Dig Dis 11: 28–33.
31. Jeffreys M, Stevanovic V, Tobias M, Lewis C, Ellison-Loschmann L, et al. (2005)
Ethnic inequalities in cancer survival in New Zealand: linkage study. Am J Public
Health 95: 834–837.
32. Dubecz A, Sepesi B, Salvador R, Polomsky M, Watson TJ, et al. (2010) Surgical
resection for locoregional esophageal cancer is underutilized in the United
States. J Am Coll Surg 211: 754–761.
33. Boffetta P, Hecht S, Gray N, Gupta P, Straif K (2008) Smokeless tobacco and
cancer. Lancet Oncol 9: 667–675.
34. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, et al. (2009) A review of
human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted
fish. Lancet Oncol 10: 1033–1034.
35. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, et al. (2010)
Cohort Profile: The Golestan Cohort Study–a prospective study of oesophageal
cancer in northern Iran. Int J Epidemiol. pp 52–59.
36. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, et al. (2002) Morphine
stimulates angiogenesis by activating proangiogenic and survival-promoting
signaling and promotes breast tumor growth. Cancer Res 62: 4491–4498.
37. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J (2006) Methylnal-
trexone inhibits opiate and VEGF-induced angiogenesis: role of receptor
transactivation. Microvasc Res 72: 3–11.
38. Kranzfelder M, Buchler P, Lange K, Friess H (2010) Treatment options for
squamous cell cancer of the esophagus: a systematic review of the literature. J Am
Coll Surg 210: 351–359.
39. Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, et al. (2005) Survival after
surgery for oesophageal cancer: a population-based study. Lancet Oncol 6:
864–870.
40. Malthaner R, Wong RK, Spithoff K (2010) Preoperative or postoperative
therapy for resectable oesophageal cancer: an updated practice guideline. Clin
Oncol (R Coll Radiol ) 22: 250–256.
41. Hajian-Tilaki KO (2001) Factors affecting the survival of patients with
oesophageal carcinoma under radiotherapy in the north of Iran. Br J Cancer
85: 1671–1674.
42. Salek R, Bezenjani SE, Saedi HS, Ashkiki MH, Hosainzade SM, et al. (2009) A
geographic area with better outcome of esophageal carcinoma: is there an effect
of ethnicity and etiologic factors? Oncology 77: 172–177.
43. Gaur P, Sepesi B, Hofstetter WL, Correa AM, Bhutani MS, et al. (2010)
Endoscopic esophageal tumor length: a prognostic factor for patients with
esophageal cancer. Cancer.
44. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, et al. (1999)
Prognostic factors of oesophageal squamous cell carcinoma from the perspective
of molecular biology. Br J Cancer 80: 1281–1288.
45. Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, et al. (2002) An
analysis of multiple staging management strategies for carcinoma of the
esophagus: computed tomography, endoscopic ultrasound, positron emission
tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 74: 1026–1032.
46. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD
(2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer
98: 547–557.
Prognosis of OSCC in Golestan, Iran
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22152
